Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

NCT02175186 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Gastritis
Gastroduodenal Ulcer

Interventions

DRUG: ALBIS
DRUG: Placebo

Sponsor

Young-Hak Kim, MD, PhD